![BUTTERFLY_HERO_4](https://eprontia.com/wp-content/uploads/2021/12/BUTTERFLY_HERO_4.png)
Prescribe EPRONTIA® by name — the ONLY oral liquid topiramate in a ready-to-use formulation.
EPRONTIA® delivers a new approach to the molecule you know and trust for children and adults.
Topiramate is a first-line treatment for1…
-
focal and
generalized seizures -
Lennox-Gastaut
syndrome (LGS) -
migraine
prevention
![](https://eprontia.com/wp-content/uploads/2023/12/Eprontia_Bottle-Collection-V1-side-by-side_V4-041323.png)
The beyond-use date of EPRONTIA® is 90 days after a bottle is first opened.
EPRONTIA® (topiramate) oral solution, 25 mg/mL is indicated for:
- Epilepsy:
- Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older1
- Adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older1
- Migraine:
- Preventive treatment of migraine in patients 12 years of age and older1
EPRONTIA® may fulfill an unmet medical need for patients who require dosing customization, flexibility, or convenient administration, ensuring that they receive consistent potency from the first milliliter to the last.
EPRONTIA® Conversion Calculator: Calculate mg to mL with precision
Storage and Administration:
When dosing, a calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device. Once opened, unused portions should be discarded after 90 days.
The recommended dose for EPRONTIA® monotherapy for epilepsy in adults and pediatric patients 10 years of age and older is 400 mg/day in 2 divided doses. The dose should be achieved by titration according to the following schedule:
Monotherapy Titration Schedule for Adults and Pediatric Patients 10 Years and Older
Morning Dose | Evening Dose | |
---|---|---|
Week 1 | 25 mg | 25 mg |
Week 2 | 50 mg | 50 mg |
Week 3 | 75 mg | 75 mg |
Week 4 | 100 mg | 100 mg |
Week 5 | 150 mg | 150 mg |
Week 6 | 200 mg | 200 mg |
Monotherapy Target Total Maintenance Dosing for Patients 2 to 9 Years of Age
Weight (kg) | Total Daily Dose (mg/day)* Minimum Maintenance Dose |
Total Daily Dose (mg/day)* Maximum Maintenance Dose |
---|---|---|
Up to 11 | 150 | 250 |
12-22 | 200 | 300 |
23-31 | 200 | 350 |
32-38 | 250 | 350 |
Greater than 38 | 250 | 400 |
*Administered in 2 equally divided doses.
- Dosing in patients 2 to 9 years of age is weight-based
- During the titration period, the initial dose of EPRONTIA® oral solution is 25 mg/day nightly for the first week
- Based on tolerability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week
- Dosage can be increased by 25 to 50 mg/day each subsequent week as tolerated
- Titration to the minimum maintenance dose should be attempted over 5 to 7 weeks of the total titration period
- Based upon tolerability and clinical response, additional titration up to the maximum maintenance dose can be attempted at 25 to 50 mg/day weekly increments
Adult Dosing (17 Years of Age and Older) in Adjunctive Therapy for Epilepsy
Seizure Type | Daily Dose* |
---|---|
Partial-Onset or Lennox-Gastaut Syndrome | 200-400 mg |
Primary Generalized Tonic-Clonic | 400 mg |
*Administered in 2 divided doses.
- EPRONTIA® should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week
Pediatric Dosing (2-16 Years of Age) in Adjunctive Therapy for the Treatment of Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Seizures Associated With Lennox-Gastaut Syndrome
Weight (kg) | Minimum Daily Dose† (5 mg/kg/day) |
Maximum Daily Dose† (9 mg/kg/day) |
---|---|---|
11 | 55 | 99 |
22 | 110 | 198 |
31 | 155 | 279 |
38 | 190 | 342 |
50 | 250 | 400 |
†Administered in 2 divided doses. Total daily dose should not exceed 400 mg/day.
- Titration should begin at 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in 2 divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome
Dosing (12 Years of Age and Older) for the Preventive Treatment of Migraine
Morning Dose | Evening Dose | |
---|---|---|
Week 1 | None | 25 mg |
Week 2 | 25 mg | 25 mg |
Week 3 | 25 mg | 50 mg |
Week 4 | 50 mg | 50 mg |
- The recommended daily dose of EPRONTIA® oral solution as preventive treatment of migraine is 100 mg/day administered in 2 divided doses
- Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used
![ICON_25YEARS](https://eprontia.com/wp-content/uploads/2021/12/ICON_25YEARS-1.png)
Healthcare professionals have been prescribing topiramate formulations to treat their patients with epilepsy and Lennox-Gastaut Syndrome (LGS) for over 25 years. In 2004, the FDA approved topiramate for the prevention of migraine.3
EPRONTIA®, the only ready-to-use oral liquid topiramate, builds on that legacy. Please review the Important Safety Information at the bottom of this page.